'Beautiful baton pass' as Amgen picks up deCODE to validate drug targets

Amgen will pay $415 million to enhance the Thousand Oaks, California-based biotechnology powerhouse's drug discovery and development capabilities through the acquisition of deCODE Genetics, nearly three years after the Icelandic genome sequencer emerged from bankruptcy (scripintelligence.com, 22 January 2010).